美国风湿病学会关于儿童SARS-CoV-2相关多系统炎症综合征及儿童COVID-19高炎症的临床指导(第一版)
美国风湿病学会组织多学科工作组,针对儿童SARS-CoV-2相关多系统炎症综合征(MIS-C)及儿童COVID-19高炎症的管理制定临床指导。工作组基于证据报告初步拟定声明,通过改良德尔菲法(两轮匿名投票和两次网络研讨会)达成共识,最终批准128条指导声明并提炼为40条最终临床指导声明,附MIS-C诊断路径流程图。该指导为「活文件」,将随证据更新而修订。
要点
- ACR工作组批准128条指导声明,提炼为40条最终临床指导声明。
- 共识采用改良德尔菲法,9分制评估适当性,共识水平分低、中、高。
- 指导涵盖MIS-C管理及儿童COVID-19高炎症,附MIS-C诊断流程图。
核心结论
- ACR工作组批准了关于MIS-C和儿童COVID-19高炎症管理的128条指导声明,并提炼为40条最终临床指导声明。
- 该指导为「活文件」,反映当前可用证据与专家意见,将随证据更新而修订。
研究设计与样本
- ACR召集多学科工作组,由9名儿童风湿病学家、2名成人风湿病学家、2名儿童心脏病学家、2名儿童感染病学家和1名儿童重症监护医师组成。
- 基于证据报告初步拟定声明,通过改良德尔菲法(两轮匿名投票和两次网络研讨会)达成共识,采用9分制评估适当性(1-3不适当,4-6不确定,7-9适当),共识水平分低、中、高。
主要发现
- ACR工作组共批准128条指导声明,涉及MIS-C和儿童COVID-19高炎症的管理。
- 这些声明被提炼为40条最终临床指导声明,并附有描述MIS-C诊断路径的流程图。
关键数值与推荐
- 9分制适当性评分:中位数1-3为不适当,4-6为不确定,7-9为适当。
- 共识水平根据投票在数值量表上的离散程度评为低、中或高。
- 批准的指导声明为分类为适当且具有中等或高共识水平的声明(投票前预先指定)。
临床怎么用
- 临床可参考40条最终指导声明管理儿童SARS-CoV-2相关MIS-C及儿童COVID-19高炎症。
- 可使用附带的流程图辅助MIS-C的诊断路径。
局限性
- 指导基于当前可用证据与专家意见,将随证据更新而修订。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To provide guidance on the management of multisystem inflammatory syndrome in children (MIS-C), a condition characterized by fever, inflammation, and multiorgan dysfunction that manifests late in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and to provide recommendations for children with hyperinflammation during coronavirus disease 2019 (COVID-19), the acute, infectious phase of SARS-CoV-2 infection. METHODS: A multidisciplinary task force was convened by the American College of Rheumatology (ACR) to provide guidance on the management of MIS-C associated with SARS-CoV-2 and hyperinflammation in COVID-19. The task force was composed of 9 pediatric rheumatologists, 2 adult rheumatologists, 2 pediatric cardiologists, 2 pediatric infectious disease specialists, and 1 pediatric critical care physician. Preliminary statements addressing clinical questions related to MIS-C and hyperinflammation in COVID-19 were developed based on evidence reports. Consensus was built through a modified Delphi process that involved 2 rounds of anonymous voting and 2 webinars. A 9-point scale was used to determine the appropriateness of each statement (median scores of 1-3 for inappropriate, 4-6 for uncertain, and 7-9 for appropriate), and consensus was rated as low, moderate, or high based on dispersion of the votes along the numeric scale. Approved guidance statements were those that were classified as appropriate with moderate or high levels of consensus, as prespecified prior to voting. RESULTS: The ACR task force approved a total of 128 guidance statements addressing the management of MIS-C and hyperinflammation in pediatric COVID-19. These statements were refined into 40 final clinical guidance statements, accompanied by a flow diagram depicting the diagnostic pathway for MIS-C. CONCLUSION: Our understanding of SARS-CoV-2-related syndromes in the pediatric population continues to evolve. The guidance provided in this "living document" reflects currently available evidence, coupled with expert opinion, and will be revised as further evidence becomes available.
引用
- Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 1. Arthritis Rheumatol. 2020. PMID: 32705809. doi:10.1002/art.41454
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。